248 related articles for article (PubMed ID: 16777680)
21. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
23. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y
Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771
[TBL] [Abstract][Full Text] [Related]
24. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.
Brignole C; Marimpietri D; Gambini C; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):199-204. PubMed ID: 12880982
[TBL] [Abstract][Full Text] [Related]
25. EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery.
Haeri A; Zalba S; Ten Hagen TL; Dadashzadeh S; Koning GA
Colloids Surf B Biointerfaces; 2016 Oct; 146():657-69. PubMed ID: 27434152
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells.
Limasale YD; Tezcaner A; Özen C; Keskin D; Banerjee S
Int J Pharm; 2015 Feb; 479(2):364-73. PubMed ID: 25595386
[TBL] [Abstract][Full Text] [Related]
27. PEG-immunoliposome.
Maruyama K
Biosci Rep; 2002 Apr; 22(2):251-66. PubMed ID: 12428903
[TBL] [Abstract][Full Text] [Related]
28. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer.
Vega J; Ke S; Fan Z; Wallace S; Charsangavej C; Li C
Pharm Res; 2003 May; 20(5):826-32. PubMed ID: 12751641
[TBL] [Abstract][Full Text] [Related]
29. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
30. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
31. Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody.
Lundberg BB; Griffiths G; Hansen HJ
Drug Deliv; 2007 Mar; 14(3):171-5. PubMed ID: 17454037
[TBL] [Abstract][Full Text] [Related]
32. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
34. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.
Cheng WW; Allen TM
Expert Opin Drug Deliv; 2010 Apr; 7(4):461-78. PubMed ID: 20331354
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic Effects of PEGylated Anti-EGFR Immunoliposomes Combined with Doxorubicin and Rhenium-188 Against Cancer Cells.
Hsu WC; Cheng CN; Lee TW; Hwang JJ
Anticancer Res; 2015 Sep; 35(9):4777-88. PubMed ID: 26254368
[TBL] [Abstract][Full Text] [Related]
36. Development of anti-p185HER2 immunoliposomes for cancer therapy.
Park JW; Hong K; Carter P; Asgari H; Guo LY; Keller GA; Wirth C; Shalaby R; Kotts C; Wood WI
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1327-31. PubMed ID: 7877976
[TBL] [Abstract][Full Text] [Related]
37. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
[TBL] [Abstract][Full Text] [Related]
38. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells.
Wöll S; Dickgiesser S; Rasche N; Schiller S; Scherließ R
Eur J Pharm Biopharm; 2019 Mar; 136():203-212. PubMed ID: 30677497
[TBL] [Abstract][Full Text] [Related]
39. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
Roth A; Drummond DC; Conrad F; Hayes ME; Kirpotin DB; Benz CC; Marks JD; Liu B
Mol Cancer Ther; 2007 Oct; 6(10):2737-46. PubMed ID: 17938267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
